Developer docs
API playgroundTry for free, no card

Search company profiles

eli lilly canada

Full company profile

uuid02malck

Namestring
eli lilly canada
Legal namestring
Eli Lilly Canada Inc
Websiteurl
lillypro.ca
Company typeenum
Public
Founded yearstring
-
Descriptiontext

Eli Lilly Canada Inc. is the Canadian operating subsidiary of Eli Lilly and Company (NYSE: LLY), headquartered in Toronto. The entity is responsible for distributing Lilly's prescription pharmaceutical products to Canadian patients and providing clinical information resources to Canadian Healthcare Professionals. Its core commercial interface is a two-portal model: a DIN-gated patient portal at ca.lilly.com that requires a valid Drug Identification Number to access product information, and an authenticated Healthcare Professional portal at account.lilly.com for clinical and product resources. A Customer Response Centre (1-888-545-5972) provides direct phone support for both audiences.

The subsidiary's business model is structurally simple: it monetizes indirectly as the Canadian distribution arm of the parent's patented pharmaceutical portfolio, generating revenue through prescription sales channeled via Canadian pharmacies and healthcare providers. Pricing is not publicly disclosed; product information is gated behind DIN verification, which functions both as a regulatory compliance mechanism (Health Canada) and a lead-qualification filter. Customer segments consist of prescribed patients (primary) and Healthcare Professionals (secondary), with no named enterprise anchors disclosed and no headcount figure provided.

Eli Lilly Canada currently faces a Canada Revenue Agency tax audit and lawsuit related to its 2020 filings and transfer pricing with Irish affiliates, which introduces regulatory and financial uncertainty. No funding rounds, M&A activity, leadership changes, or direct AI/technology investments are disclosed at the subsidiary level. Strategic positioning is fully derivative of the parent's global pipeline, including GLP-1 franchises and the experimental obesity candidate retatrutide.

Short descriptiontext

Eli Lilly Canada Inc. is the Toronto-based Canadian subsidiary of Eli Lilly and Company (NYSE: LLY), distributing the parent's prescription pharmaceutical products to Canadian patients with valid DINs and providing clinical resources to Healthcare Professionals via dedicated portals and a Customer Response Centre.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
prescription pharmaceuticals, patient support services, healthcare professional portal, clinical information access, DIN verification
Industry1 code
PRIMARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
No data
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eli Lilly Canada Inc provides prescription pharmaceutical products to Canadian patients who have a valid Drug Identification Number (DIN), and clinical/product information resources to Canadian Healthcare Professionals through a dedicated authenticated portal. The organization supports patients and HCPs via a Customer Response Centre (1-888-545-5972) and a tiered website (ca.lilly.com) that gates content by DIN verification or HCP sign-in.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Eli Lilly Canada operates a pharmaceutical products information portal for patients and healthcare professionals. The company offers a patient-facing website that requires a valid DIN (Drug Identification Number) for access, along with a separate Healthcare Professional portal. The company provides prescription medications and maintains a Customer Response Centre at 1-888-545-5972. Specific pharmaceutical product names and details are accessible through authenticated access to these portals.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pfizer Canada ULC is the Canadian subsidiary of Pfizer Inc., a global pharmaceutical leader. Direct comparable to Eli Lilly Canada as both distribute the parent's prescription pharmaceutical portfolio to Canadian patients and HCPs, operate similar regulatory and patient-support models, and compete in identical therapeutic categories.

TypeDirect peer
Description

Hoffmann-La Roche Limited (Roche Canada) is the Canadian subsidiary of F. Hoffmann-La Roche. Highly comparable to Eli Lilly Canada: distributes the parent's prescription pharmaceutical products in Canada, supports patients and HCPs, and operates across multiple therapeutic areas including oncology, the parent's flagship franchise.

TypeDirect peer
Description

Novartis Pharmaceuticals Canada Inc. is the Canadian subsidiary of Novartis AG. Comparable to Eli Lilly Canada as a major Swiss pharma subsidiary distributing prescription products across cardiovascular, oncology, immunology, and neuroscience in Canada, with similar HCP engagement infrastructure.

TypeDirect peer
Description

Merck Canada Inc., the Canadian subsidiary of Merck & Co. (known as MSD outside North America), directly parallels Eli Lilly Canada. Both distribute the parent's prescription drug portfolio in Canada, serve patients and HCPs, and compete in overlapping therapeutic areas including oncology, vaccines, and diabetes.

5AstraZeneca Canada
TypeDirect peer
Description

AstraZeneca Canada Inc. is the Canadian subsidiary of AstraZeneca PLC. Direct comparable to Eli Lilly Canada: distributes prescription pharmaceuticals across oncology, cardiovascular, renal-metabolic (including diabetes), and respiratory in Canada, with parallel patient and HCP engagement models.

TypeDirect peer
Description

GlaxoSmithKline Inc. (GSK Canada) is the Canadian subsidiary of GSK plc. Comparable to Eli Lilly Canada as a major UK pharma subsidiary distributing prescription pharmaceuticals and vaccines in Canada, with similar regulatory positioning and HCP-facing infrastructure.

TypeDirect peer
Description

Sanofi-Aventis Canada Inc. is the Canadian subsidiary of Sanofi S.A. Direct comparable to Eli Lilly Canada as a global pharma subsidiary distributing prescription pharmaceuticals (notably in diabetes, where both companies compete via GLP-1 and insulin franchises) and operating patient/HCP support channels in Canada.

8AbbVie Canada
TypeDirect peer
Description

AbbVie Corporation is the Canadian subsidiary of AbbVie Inc. Highly comparable to Eli Lilly Canada: distributes a diversified prescription pharmaceutical portfolio in Canada, operates similar patient and HCP engagement models, and competes across immunology, oncology, and neuroscience.

9Bristol Myers Squibb Canada
TypeDirect peer
Description

Bristol-Myers Squibb Canada Co. is the Canadian subsidiary of Bristol Myers Squibb Company. Comparable to Eli Lilly Canada as a major US pharma subsidiary distributing prescription pharmaceuticals across oncology, hematology, immunology, and cardiovascular disease in Canada.

TypeDirect peer
Description

Janssen Inc. (Johnson & Johnson Innovative Medicine) is the Canadian pharmaceutical subsidiary of Johnson & Johnson. Comparable to Eli Lilly Canada as a major US pharma subsidiary distributing prescription pharmaceuticals across oncology, immunology, neuroscience, and pulmonary hypertension in Canada.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

eli lilly canada

Eli Lilly Canada Inc. is the Toronto-based Canadian subsidiary of Eli Lilly and Company (NYSE: LLY), distributing the parent's prescription pharmaceutical products to Canadian patients with valid DINs and providing clinical resources to Healthcare Professionals via dedicated portals and a Customer Response Centre.

What eli lilly canada does

Eli Lilly Canada Inc. is the Canadian operating subsidiary of Eli Lilly and Company (NYSE: LLY), headquartered in Toronto. The entity is responsible for distributing Lilly's prescription pharmaceutical products to Canadian patients and providing clinical information resources to Canadian Healthcare Professionals. Its core commercial interface is a two-portal model: a DIN-gated patient portal at ca.lilly.com that requires a valid Drug Identification Number to access product information, and an authenticated Healthcare Professional portal at account.lilly.com for clinical and product resources. A Customer Response Centre (1-888-545-5972) provides direct phone support for both audiences.

The subsidiary's business model is structurally simple: it monetizes indirectly as the Canadian distribution arm of the parent's patented pharmaceutical portfolio, generating revenue through prescription sales channeled via Canadian pharmacies and healthcare providers. Pricing is not publicly disclosed; product information is gated behind DIN verification, which functions both as a regulatory compliance mechanism (Health Canada) and a lead-qualification filter. Customer segments consist of prescribed patients (primary) and Healthcare Professionals (secondary), with no named enterprise anchors disclosed and no headcount figure provided.

Eli Lilly Canada currently faces a Canada Revenue Agency tax audit and lawsuit related to its 2020 filings and transfer pricing with Irish affiliates, which introduces regulatory and financial uncertainty. No funding rounds, M&A activity, leadership changes, or direct AI/technology investments are disclosed at the subsidiary level. Strategic positioning is fully derivative of the parent's global pipeline, including GLP-1 franchises and the experimental obesity candidate retatrutide.

eli lilly canada firmographics

Firmographics
Name
eli lilly canada
Legal name
Eli Lilly Canada Inc
Website
https://lillypro.ca
Company type
Public
Operating status
Operating
Short description
Eli Lilly Canada Inc. is the Toronto-based Canadian subsidiary of Eli Lilly and Company (NYSE: LLY), distributing the parent's prescription pharmaceutical products to Canadian patients with valid DINs and providing clinical resources to Healthcare Professionals via dedicated portals and a Customer Response Centre.
Ownership category
akta.pro rank

eli lilly canada industry classification

Industry
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Prescription pharmaceuticals
  • Patient support services
  • Healthcare professional portal
  • Clinical information access
  • DIN verification

Where eli lilly canada is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Markets served

eli lilly canada business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels2 records

eli lilly canada product offering

Product offering

Core offering

Eli Lilly Canada Inc provides prescription pharmaceutical products to Canadian patients who have a valid Drug Identification Number (DIN), and clinical/product information resources to Canadian Healthcare Professionals through a dedicated authenticated portal. The organization supports patients and HCPs via a Customer Response Centre (1-888-545-5972) and a tiered website (ca.lilly.com) that gates content by DIN verification or HCP sign-in.

Product overview

Eli Lilly Canada operates a pharmaceutical products information portal for patients and healthcare professionals. The company offers a patient-facing website that requires a valid DIN (Drug Identification Number) for access, along with a separate Healthcare Professional portal. The company provides prescription medications and maintains a Customer Response Centre at 1-888-545-5972. Specific pharmaceutical product names and details are accessible through authenticated access to these portals.

Differentiator

Problem solved

Functional benefit

Companies that use eli lilly canada

Customer profile

Segments2 records

eli lilly canada technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

eli lilly canada partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

eli lilly canada competitors and assessment

Company assessment

Direct peers

  • Pfizer Canada: Pfizer Canada ULC is the Canadian subsidiary of Pfizer Inc., a global pharmaceutical leader. Direct comparable to Eli Lilly Canada as both distribute the parent's prescription pharmaceutical portfolio to Canadian patients and HCPs, operate similar regulatory and patient-support models, and compete in identical therapeutic categories.
  • Roche Canada: Hoffmann-La Roche Limited (Roche Canada) is the Canadian subsidiary of F. Hoffmann-La Roche. Highly comparable to Eli Lilly Canada: distributes the parent's prescription pharmaceutical products in Canada, supports patients and HCPs, and operates across multiple therapeutic areas including oncology, the parent's flagship franchise.
  • Novartis Pharmaceuticals Canada: Novartis Pharmaceuticals Canada Inc. is the Canadian subsidiary of Novartis AG. Comparable to Eli Lilly Canada as a major Swiss pharma subsidiary distributing prescription products across cardiovascular, oncology, immunology, and neuroscience in Canada, with similar HCP engagement infrastructure.
  • Merck Canada: Merck Canada Inc., the Canadian subsidiary of Merck & Co. (known as MSD outside North America), directly parallels Eli Lilly Canada. Both distribute the parent's prescription drug portfolio in Canada, serve patients and HCPs, and compete in overlapping therapeutic areas including oncology, vaccines, and diabetes.
  • AstraZeneca Canada: AstraZeneca Canada Inc. is the Canadian subsidiary of AstraZeneca PLC. Direct comparable to Eli Lilly Canada: distributes prescription pharmaceuticals across oncology, cardiovascular, renal-metabolic (including diabetes), and respiratory in Canada, with parallel patient and HCP engagement models.
  • GSK Canada: GlaxoSmithKline Inc. (GSK Canada) is the Canadian subsidiary of GSK plc. Comparable to Eli Lilly Canada as a major UK pharma subsidiary distributing prescription pharmaceuticals and vaccines in Canada, with similar regulatory positioning and HCP-facing infrastructure.
  • Sanofi Canada: Sanofi-Aventis Canada Inc. is the Canadian subsidiary of Sanofi S.A. Direct comparable to Eli Lilly Canada as a global pharma subsidiary distributing prescription pharmaceuticals (notably in diabetes, where both companies compete via GLP-1 and insulin franchises) and operating patient/HCP support channels in Canada.
  • AbbVie Canada: AbbVie Corporation is the Canadian subsidiary of AbbVie Inc. Highly comparable to Eli Lilly Canada: distributes a diversified prescription pharmaceutical portfolio in Canada, operates similar patient and HCP engagement models, and competes across immunology, oncology, and neuroscience.
  • Bristol Myers Squibb Canada: Bristol-Myers Squibb Canada Co. is the Canadian subsidiary of Bristol Myers Squibb Company. Comparable to Eli Lilly Canada as a major US pharma subsidiary distributing prescription pharmaceuticals across oncology, hematology, immunology, and cardiovascular disease in Canada.
  • Johnson & Johnson Innovative Medicine Canada: Janssen Inc. (Johnson & Johnson Innovative Medicine) is the Canadian pharmaceutical subsidiary of Johnson & Johnson. Comparable to Eli Lilly Canada as a major US pharma subsidiary distributing prescription pharmaceuticals across oncology, immunology, neuroscience, and pulmonary hypertension in Canada.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

eli lilly canada financial estimates

Financial estimate

Revenue estimate

Valuation estimate

eli lilly canada leadership team

Management profile

Number of profiles

eli lilly canada funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

eli lilly canada M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eli lilly canada

What does eli lilly canada do?

Eli Lilly Canada Inc provides prescription pharmaceutical products to Canadian patients who have a valid Drug Identification Number (DIN), and clinical/product information resources to Canadian Healthcare Professionals through a dedicated authenticated portal. The organization supports patients and HCPs via a Customer Response Centre (1-888-545-5972) and a tiered website (ca.lilly.com) that gates content by DIN verification or HCP sign-in.

Is eli lilly canada a public or private company?

eli lilly canada is a public company. It is currently operating.

When was eli lilly canada founded?

eli lilly canada was founded in -1.

Where is eli lilly canada based?

eli lilly canada is headquartered in Toronto, Canada, in the North America region.

Who are eli lilly canada's main competitors?

Direct peers on record are Pfizer Canada, Roche Canada, Novartis Pharmaceuticals Canada, Merck Canada, AstraZeneca Canada, GSK Canada, Sanofi Canada, AbbVie Canada, Bristol Myers Squibb Canada and Johnson & Johnson Innovative Medicine Canada.

Does eli lilly canada have an API?

No public API is recorded for eli lilly canada.

What industry is eli lilly canada in?

Its primary akta.pro industry code is HLAIAJAO, Compounding Ingredient & API Distributors (Pharma Supply). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Globe and MailCanada confronts challenges as global race for health innovation acceleratesCanada's Health Innovation Challenge, hosted by The Globe and Mail and Lilly Canada, highlighted that Canadians have access to only 18% of global medications and rank last in the G7 for timely access. The event also noted Canada has 2.7 physicians per 1,000 people, and industry leaders urged a comprehensive strategy to harness local talent.EdmontonjournalCRA looking into pharmaceutical giant Eli Lilly Canada's taxesThe Canada Revenue Agency (CRA) has launched an audit and filed a lawsuit against Eli Lilly Canada, alleging the company did not pay sufficient taxes in 2020 due to suspiciously low profit margins. The CRA suspects transfer pricing issues involving transactions with offshore entities, particularly in Ireland, while Eli Lilly Canada disputes these characterizations and intends to respond through the court process. This ongoing legal battle centers on whether the pharmaceutical giant appropriately priced goods and services sold between its Canadian and foreign divisions.NewswirePUBLIC SAFETY NOTICE: UNAPPROVED AND ILLEGAL RETATRUTIDE PRODUCTSLilly Canada warned the public about unapproved and illegal retatrutide products sold on the black market, noting the molecule is in Phase 3 trials and not approved for human use. The company is working with Health Canada and law enforcement, and has filed lawsuits and referred operators in the U.S. It also urged reporting of suspected products.GlobeNewswireObesity Canada and Lilly advance Canadian obesity research with a new fellowship programObesity Canada and Lilly Canada announced two postdoctoral fellows selected for the inaugural Canadian Obesity Fellowship Program, each receiving a $30,000 award matched by their institutions. The program supports research on childhood obesity and osteoarthritis treatment for individuals with obesity.GlobeNewswireJDRF & Lilly Canada fund UBC research that could allow people with type 1 diabetes to produce their own insulinJDRF and Lilly Canada awarded a CAN$60,000 post-doctoral fellowship to Dr. Cara Ellis at UBC to study cell-based therapies for type 1 diabetes. The research aims to produce insulin-producing cells from embryonic stem cells, which could be manufactured in unlimited numbers, potentially offering a cure.